Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology launched the Reimagine Recurrent LGSOC campaign to drive awareness of AVMAPKI FAKZYNJA CO-PACK, the only FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer. The initiative includes new websites and digital resources designed to educate healthcare professionals and patients about the specific treatment option and manage care expectations.
Key figures
- Drug Name
- AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets)
- Kras mutation rate
- 30%
- Us lgsoc prevalence
- 6,000-8,000
- Worldwide lgsoc prevalence
- 80,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.